Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 7/20 | 0.41 |
| ▸ | ALB | P02768 | 4/20 | 0.34 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL180974 | 0.94 | HDAC3 (0.48) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL15069739 | 0.83 | FOLH1 (0.45) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL8530125 | 0.80 | ALDH1A1 (0.51) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL4335255 | 0.80 | FOLH1 (0.43) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL44176 | 0.79 | HDAC3 (0.42) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL3067420 | 0.77 | HDAC3 (0.40) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1438383 | 0.76 | ALDH1A1 (0.42) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL18123719 | 0.75 | MEN1 (0.47) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL2804782 | 0.75 | ALDH1A1 (0.53) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL30773222 | 0.74 | ALDH1A1 (0.49) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 318 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150246942-A1 | ALIGNMENT OF NANOMATERIALS AND MICROMATERIALS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2015-09-03 | — | — | US | claimed |
| EP-2478049-B1 | A POLYMER SUPPORT | UNIV CAPE TOWN (ZA) | 2015-02-25 | — | — | EP | claimed |
| US-20140024818-A1 | ALIGNMENT OF NANOMATERIALS AND MICROMATERIALS | NATIONAL SCIENCE FOUNDATION | 2014-01-23 | — | — | US | claimed |
| US-20130183270-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. (US) | 2013-07-18 | — | — | US | claimed |
| US-8420802-B2 | Polymer support | UNIVERSITY OF CAPE TOWN (ZA) | 2013-04-16 | — | — | US | claimed |
| US-20120270787-A1 | COMPOUNDS HAVING PEPTIDES CONJUGATED TO BONE TARGETING MOIETIES AND METHODS OF MAKING AND USING THEREOF | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2012-10-25 | — | — | US | claimed |
| EP-2488208-A1 | COMPOUNDS HAVING PEPTIDES CONJUGATED TO BONE TARGETING MOIETIES AND METHODS OF MAKING AND USING THEREOF | The Governors of the University of Alberta (CA) | 2012-08-22 | — | — | EP | claimed |
| EP-2478049-A1 | A POLYMER SUPPORT | University of Cape Town (ZA) | 2012-07-25 | — | — | EP | claimed |
| US-20120178916-A1 | Polymer Support | UNIVERSITY OF CAPE TOWN (ZA) | 2012-07-12 | — | — | US | claimed |
| EP-2410991-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | SDG, INC. (an Ohio Corporation ) (US) | 2012-02-01 | — | — | EP | claimed |
| WO-2011083360-A1 | A POLYMER SUPPORT | UNIVERSITY OF CAPE TOWN (ZA) | 2011-07-14 | — | — | WO | claimed |
| WO-2011045668-A1 | COMPOUNDS HAVING PEPTIDES CONJUGATED TO BONE TARGETING MOIETIES AND METHODS OF MAKING AND USING THEREOF | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2011-04-21 | — | — | WO | claimed |
| WO-2010111271-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | SDG, INC. (AN OHIO CORPORATION) (US) | 2010-09-30 | — | — | WO | claimed |
| US-20100080773-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. | 2010-04-01 | — | — | US | claimed |
| US-20030148304-A1 | Method for immobilisation | KAROLINSKA INNOVATIONS AB (SE) | 2003-08-07 | — | — | US | claimed |
| EP-1235937-A1 | METHOD FOR IMMOBILISATION | Karolinska Innovations AB (SE) | 2002-09-04 | — | — | EP | claimed |
| WO-2001042501-A1 | METHOD FOR IMMOBILISATION | KAROLINSKA INNOVATIONS AB (SE) | 2001-06-14 | — | — | WO | claimed |
| US-20250352663-A1 | Nanoclusters Functionalized with Adenosine Triphosphate or an Analogue and Their Use | UNIV LELAND STANFORD JUNIOR (US) | 2025-11-20 | — | — | US | disclosed |
| WO-2001016375-A2 | HIGH SPEED PARALLEL MOLECULAR NUCLEIC ACID SEQUENCING | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-03-08 | — | — | WO | disclosed |
| US-5965106-A | ADMINISTERING TARGETING MOIETY COUPLED TO AFFINITY COMPONENT, WHEREIN TARGETING MOIETY HAS AFFINITY FOR BINDING SITES IN TARGET AREA, AND BINDING PARTNER TO AFFINITY COMPONENT COUPLED TO FUNCTIONAL MOIETY TO LOCALIZE FUNCTIONAL MOIETY IN TARGET | PERIMMUNE HOLDINGS, INC. (US) | 1999-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270787-A1 | COMPOUNDS HAVING PEPTIDES CONJUGATED TO BONE TARGETING MOIETIES AND METHODS OF MAKING AND USING THEREOF | SOST, CALCRL, CALCA | HDAC3 3001/4885HDAC4 1552/4885HDAC1 3350/4885 |
| US-20100080773-A1 | Orally Bioavailable Lipid-Based Constructs | FABP2, FABP1, LIPC | HDAC3 3495/4885HDAC4 4132/4885HDAC1 4001/4885 |
| US-20130183270-A1 | Orally Bioavailable Lipid-Based Constructs | FABP2, FABP1, LIPC | HDAC3 3495/4885HDAC4 4132/4885HDAC1 4001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.